Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Employment agrmnt
Quarterly results
Appointed director

Surface Oncology, Inc. (SURF) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 4 Adams Chandra (Deputy GC) has filed a Form 4 on Surface Oncology, Inc.
Txns: Sold 3,901 shares @ $0.94, valued at $3.7k
08/11/2023 4 FEES JESSICA (CFO) has filed a Form 4 on Surface Oncology, Inc.
Txns: Sold 9,434 shares @ $0.94, valued at $8.9k
08/11/2023 4 ONEILL ALISON (Chief Medical Officer) has filed a Form 4 on Surface Oncology, Inc.
Txns: Sold 7,042 shares @ $0.94, valued at $6.6k
08/11/2023 4 ROSS ROBERT W. (CEO) has filed a Form 4 on Surface Oncology, Inc.
Txns: Sold 16,713 shares @ $0.94, valued at $15.7k
08/02/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/02/2023 8-K Quarterly results
07/26/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
07/20/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/12/2023 425 Form 425 - Prospectuses and communications, business combinations:
07/12/2023 425 Form 425 - Prospectuses and communications, business combinations:
07/07/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
07/03/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION",
"Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm",
"Financial Statements and Supplementary Data",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations"
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/16/2023 8-K Amended existing or entered into new employment agreement with an officer
Docs: "Agreement and Plan of Merger, by and among Surface Oncology, Inc., Coherus BioSciences, Inc., Crimson Merger Sub I, Inc. and Crimson Merger Sub II, LLC, (Form of CVR Agreement included as Exhibit A thereto)",
"Form of Executive Agreement Amendment",
"Form of C-Suite Executive Agreement Amendment",
"Form of Retention Agreement",
"Coherus to Acquire Surface Oncology"
06/16/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy